Prescribing Venlafaxine

Why Venlafaxine Still Matters

Venlafaxine is the standard SNRI, the one clinicians rely on day to day. It was the first to arrive (1993), it has the deepest evidence base of any SNRI, and in head-to-head data it does slightly more than an SSRI. In the Cipriani 2018 network meta-analysis of 21 antidepressants, it ranked near the top for efficacy. Its dose-response curve is clean and reliable, so when a patient stalls at 150 mg, pushing higher is a real strategy and not wishful thinking. It treats depression and anxiety, it is useful for neuropathic pain and migraine prophylaxis, and it is a cheap generic.

It isn't first-line mostly for one reason: its discontinuation syndrome is among the worst in psychiatry. A short half-life plus dual reuptake blockade means that a missed dose or two produces the classic brain zaps, vertigo, nausea, and dysphoria that patients describe as some of the most miserable weeks of their treatment. That one liability keeps venlafaxine off most experts' lists of preferred agents (fluoxetine, sertraline, escitalopram, bupropion, mirtazapine) and pushes it into a second-line role.

Think of venlafaxine less as a starting antidepressant and more as your reliable second move, for when the SSRI has failed, when the depression comes with pain, migraine, or prominent apathy, or when you need a dual-mechanism agent for treatment resistance.

Part 1: Indications

FDA-Approved Uses

• Major depressive disorder
• Generalized anxiety disorder (GAD)
• Social anxiety disorder
• Panic disorder

(Effexor XR carries the depression, GAD, social anxiety, and panic indications; the older immediate-release Effexor is approved for depression.)

The Evidence-Based Clinical Uses

Major depression

Venlafaxine works, and by a small margin it may work slightly better than SSRIs. The Thase pooled analysis (851 venlafaxine vs. 748 SSRI vs. 446 placebo) found 45% remission on venlafaxine vs. 35% on SSRI, a real but modest edge. As an NNT, that is roughly 1 extra remission for every 10 patients treated with venlafaxine instead of an SSRI; some analyses put the NNT closer to 17. Either way the advantage is real but not large, and it is no reason to reach for venlafaxine first when SSRIs are gentler and easier to stop.

Generalized anxiety disorder

An FDA indication and a real strength. Venlafaxine has a robust spectrum of anti-anxiety activity, though probably not as broad as the SSRIs. Effect sizes in GAD are modest (0.2 to 0.3), on par with other antidepressants and below benzodiazepines, but venlafaxine is a legitimate, non-habit-forming option.

Social anxiety and panic disorder

Both are on the label for Effexor XR. Social anxiety responds more slowly than depression (a quarter of non-responders at 2 months will convert to responders by month 3), so run the trial at least 3 to 6 months before calling it a failure, and expect frequent relapse if you stop.

Treatment-resistant depression

Treatment-resistant depression is where venlafaxine fits best. It is a standard switch option after a failed SSRI and an accepted augmenter in TRD algorithms. Its dose-response curve is the asset in TRD: efficacy keeps climbing toward ~375 mg (though with diminishing returns above 150 mg), which is unusual, since most antidepressants plateau. Two important caveats from recent trials:

• In ASCERTAIN-TRD (2024), switching to venlafaxine XR or duloxetine (MADRS −13.2) was outperformed by rTMS augmentation (MADRS −17.4; NNT 7 for response favoring rTMS). Venlafaxine remains a reasonable switch, but offer rTMS earlier when the patient is amenable.
• For deeply resistant or melancholic depression, tricyclics and MAOIs may still outperform a venlafaxine switch.

Neuropathic and somatic pain: an underused strength

Venlafaxine's dual mechanism gives it real analgesic activity independent of mood. For neuropathic pain, SNRIs and tricyclics are the antidepressant mainstays, and venlafaxine's NNT of ~3 for neuropathic pain beats duloxetine's ~5.2. Pain relief typically requires higher doses (often 150 to 225 mg, up to 300 to 375 mg in pain clinics), because it depends on engaging the noradrenergic mechanism. It is also useful for the vague somatic pain that accompanies depression.

Migraine and tension headache prophylaxis

Positive data, best at higher doses. Among antidepressants, tricyclics have the strongest migraine evidence, then SNRIs; SSRIs, bupropion, and mirtazapine do not prevent migraine. A depressed patient with migraines is a natural venlafaxine candidate.

PTSD

Off-label but a reasonable option (second-line, after SSRIs like sertraline). Venlafaxine beats placebo in PTSD trials. Caveat: its noradrenergic activation may fail to help, or worsen, hyperarousal symptoms (irritability, fight-or-flight). If hyperarousal dominates, favor an SSRI, and add prazosin for nightmares and sleep.

Post-ECT relapse prevention

Good evidence that venlafaxine plus lithium is as effective as nortriptyline plus lithium for preventing relapse after ECT.

Where Venlafaxine Is a Poor Choice

• OCD. Placebo-controlled data are negative; a single-blind study found it merely equivalent to clomipramine. High-dose SSRIs remain the standard.
• As a first-line antidepressant in a straightforward, uncomplicated case: the discontinuation syndrome makes an SSRI the smarter opening move.
• Uncontrolled hypertension (see below).

Who Is the Ideal Candidate?

• A patient who has failed one or more SSRIs.
• Depression with comorbid pain, neuropathy, or migraine.
• Depression with prominent apathy or low energy (the noradrenergic component may help).
• Anxiety disorders where you want a dual-mechanism, non-benzodiazepine agent.
• Someone reliable about taking a daily dose, because the discontinuation syndrome punishes missed doses.

Part 2: Before You Start: Workup and Candidacy

Venlafaxine requires far less pre-start workup than lithium. There are no mandatory baseline labs, no therapeutic drug level, and no routine ECG. You owe the patient a focused history and one vital sign.

The Minimal Workup

Who Is a Poor Candidate?

• Uncontrolled hypertension (relative; control it first).
• Recent MI or unstable cardiac disease.
• Current MAOI use or within 14 days (absolute contraindication, serotonin syndrome).
• Narrow-angle glaucoma (noradrenergic effects can raise intraocular pressure).
• A patient who cannot take a daily dose reliably, since you'd be setting up interdose withdrawal and a bad experience.

The One Conversation You Must Have Before Writing the Script

Counsel the patient about the discontinuation syndrome at initiation, not at discontinuation. Tell them plainly: "This medication works well, but it's one that your body gets used to quickly. If you stop it suddenly or miss several doses, you can feel dizzy, nauseous, get brain zaps, and feel off for a week or more. That's not dangerous, but it's unpleasant, so never stop on your own. When the time comes, we'll taper slowly together." This five-minute conversation is the most important thing you do when starting venlafaxine.

Part 3: How to Start and Dose

Formulation

Use extended-release (XR). It is once-daily, better tolerated, and produces less discontinuation syndrome and less interdose withdrawal than the immediate-release form. The old IR venlafaxine (BID/TID dosing) offers no advantage and worsens the drug's defining problem, so skip it. XR capsules come in 37.5, 75, and 150 mg; the 225 mg strength is available only as a generic extended-release tablet, not as a capsule.

Dosing by Indication

• Major depressive disorder (XR, FDA-approved): start 75 mg once daily (or 37.5 mg for 4–7 days first); usual 75–225 mg/day; XR maximum 225 mg/day.
• Generalized anxiety disorder (XR): start 75 mg (or 37.5 mg × 4–7 days); range 75–225 mg/day; max 225.
• Social anxiety disorder (XR): 75 mg/day is usually sufficient (little added benefit above 75); max 225.
• Panic disorder (XR): start 37.5 mg × 7 days → 75 mg; max 225.
• Off-label (PTSD, migraine prophylaxis, neuropathic pain): dosed in the same 75–225 mg/day range, migraine often at the higher end.

Starting Dose and Titration

• Start: 37.5–75 mg XR once daily. Starting at 37.5 mg for a week reduces early nausea; many patients can start at 75 mg.
• 75 mg is already a therapeutic dose: multiple fixed-dose trials show 75 mg separates from placebo. The old marketing line that venlafaxine needs titration to work is largely unfounded.
• Titrate to 150 mg after 1 to 2 weeks if tolerated and needed. 150 mg is the dose at which meaningful norepinephrine reuptake blockade begins and the drug becomes a true SNRI.
• Usual therapeutic range: 75–225 mg/day (the XR FDA maximum is 225 mg/day).
• Pushing higher is off-label: in TRD and pain settings, specialists escalate to ~300–375 mg/day with blood-pressure monitoring. Venlafaxine's continued dose-response makes this worthwhile in a way it isn't for most antidepressants (unlike its metabolite desvenlafaxine, which is flat), but recognize that you are above the labeled XR ceiling.
• Response is not fast: expect ~5 to 6 weeks to response and ~6 to 7 weeks to remission. Do not declare failure at week 3.

Take With Food

Take with food to reduce nausea, especially during titration.

Dose Adjustments and Special Populations

• Renal impairment: reduce total daily dose by 25–50%; for patients on hemodialysis, reduce ~50% and give the dose after the dialysis session.
• Hepatic impairment: reduce the total daily dose by ~50% in mild-to-moderate impairment (50% or more in severe impairment/cirrhosis); the XR maximum in hepatic impairment is 112.5 mg once daily.
• Geriatric: no specific dose reduction is mandated, but start low and titrate slowly; monitor blood pressure and watch for hyponatremia/SIADH.
• Pediatric: not FDA-approved (pediatric efficacy was not established), and the suicidality boxed warning applies to patients ≤24.
• Dose-dependent hypertension: check blood pressure before and during treatment, especially above 225 mg/day; reduce or stop if sustained elevation appears.

Stopping and Switching

• Discontinuation: venlafaxine has one of the harshest discontinuation syndromes of any antidepressant (short half-life, no long-acting metabolite to cushion the fall). Taper slowly rather than stopping abruptly, often over weeks to months and sometimes with a bridge to fluoxetine.
• MAOI washout: wait 14 days after stopping an MAOI before starting venlafaxine, and 7 days after stopping venlafaxine before starting an MAOI.

Part 4: Monitoring

Monitoring is short and simple. There is no therapeutic drug level to chase and no routine lab panel; for venlafaxine it is mostly blood pressure plus clinical follow-up.

Blood Pressure

Blood pressure is the one real monitoring task. The data are reassuring, and clinicians routinely get them wrong:

• Below 300 mg/day, the hypertension risk is essentially at placebo level. A meta-analysis of 3,744 patients found sustained diastolic hypertension in 2.9% on venlafaxine vs. 2.2% on placebo at doses ≤300 mg, a difference that was not significant.
• In the Effexor XR trials, sustained hypertension occurred in 0.5% to 0.9% of patients at 37.5 to 225 mg/day, and in 3% at 75 to 375 mg/day.
• Above 300 mg/day the rate of sustained elevation rose to 9.1% in that meta-analysis, about three times the rate at lower doses.

A reasonable protocol:

1. Check a baseline BP.
2. Recheck after the patient reaches their final or steady dose, whether you or the PCP does it.
3. Monitor more closely above 300 mg, and in patients who are already hypertension-prone.
4. If BP rises and is sustained: reduce the dose, treat the hypertension, or switch.

Cardiac / ECG

No routine ECG is required. QT-prolongation data are mixed but the risk is generally negligible: venlafaxine is not in the high-risk torsades category (unlike citalopram >40 mg, methadone, sotalol, dofetilide). It is considered generally safe in most cardiovascular disease, though sertraline and bupropion are the safest antidepressants in cardiac patients.

Clinical Monitoring

• Watch for emergent activation, agitation, or a manic switch early (as with any antidepressant).
• Standard suicidality monitoring, especially in the first 1 to 2 weeks and in patients under 25 (boxed warning).
• Reassess response at ~6 weeks before judging efficacy.

Part 5: Side Effects and How to Manage Them

Most venlafaxine side effects are dose-dependent, front-loaded (peaking around week 2, then fading), and manageable. The exception is the discontinuation syndrome, the drug's defining hazard, which has its own section.

Gastrointestinal (Nausea)

The most common early complaint, and dose-dependent.

Management:

• Take with food.
• Start low (37.5 mg) and titrate slowly.
• Reassure: nausea usually peaks around week 2 and settles as tolerance develops over 2 to 4 weeks.
• If severe and persistent, reduce the dose or switch.

Blood Pressure / Cardiovascular

Covered above. At therapeutic doses (<300 mg) the risk is small, and the noradrenergic mechanism is why it exists at all. If BP stays elevated, manage it by dose reduction or antihypertensive treatment.

Sexual Dysfunction

A class effect of serotonergic antidepressants, venlafaxine included. When patients are directly asked, treatment-emergent sexual dysfunction runs 58 to 73% across SSRIs and venlafaxine (vs. the much lower rates seen with spontaneous reporting). Don't assume it's absent; ask.

Management:

• Switch to or augment with bupropion or mirtazapine, which are sexual-neutral.
• Dose reduction may help.
• Counsel about the (rare) possibility of persistent post-SSRI/SNRI sexual dysfunction (PSSD).

Activation / Insomnia / Agitation

Venlafaxine can be activating (jitteriness, insomnia, agitation), reflecting its noradrenergic and serotonergic drive.

Management:

• Morning dosing if insomnia is a problem.
• Slow the titration.
• Reassure that activation often settles.

Sweating

Noradrenergically mediated diaphoresis is common with SNRIs (more prominent with the more-noradrenergic levomilnacipran). Usually tolerated; if bothersome, dose reduction or a switch.

Weight

Reassuringly modest. A large 2024 cohort (183,118 adults) found only ~0.8 lb average weight gain at 6 months on venlafaxine, comparable to duloxetine, escitalopram, and paroxetine, and clinically trivial for most patients. Less weight gain than mirtazapine. Weight is not a major differentiator here.

Bleeding

SNRIs mildly inhibit platelet aggregation and can raise GI-bleed risk, but less than SSRIs. Upper-GI-bleed risk with SSRIs is roughly 1 per 8,000 prescriptions; SNRIs are lower. The risk multiplies with NSAIDs, antiplatelet drugs, and warfarin. A PPI reduces the risk to negligible in higher-risk patients. If bleeding risk is the dominant concern, bupropion or a tricyclic is safer.

Hyponatremia / SIADH

Possible (a class effect of serotonergic antidepressants), with elevated risk in the elderly. Check a sodium if an older patient develops confusion, lethargy, or falls after starting.

Serotonin Syndrome

Rare in monotherapy; the risk climbs when venlafaxine is combined with other serotonergic agents (see Interactions). Teach the patient the warning signs (agitation, tremor, clonus, hyperthermia, diarrhea) if they're on multiple serotonergic drugs.

Part 6: Discontinuation Syndrome

Discontinuation is venlafaxine's defining hazard, and this is the section that matters most. Its withdrawal reactions are among the worst of any antidepressant: it sits on the "worst five" list alongside desvenlafaxine, duloxetine, paroxetine, and fluvoxamine. This one liability is the main reason expert panels keep it off the first-line list.

Why It Happens

Venlafaxine has a short half-life (~5 hours; the active metabolite desvenlafaxine ~11 hours), so serum levels fall fast once dosing stops or a dose is missed. The dual serotonergic-noradrenergic dependence compounds the abstinence effect.

What It Looks Like

In a Mass General report, 7 of 9 patients stopped on venlafaxine XR had discontinuation reactions vs. 2 of 9 on placebo. Symptoms range from barely perceptible lightheadedness to severe vertigo, nausea, insomnia, tearfulness, irritability, flu-like malaise, and brain zaps (electric-shock sensations). Severity tracks with dose and abruptness.

How to Prevent and Manage It

Part 7: Overdose and Boxed Warning

Overdose

Venlafaxine is more dangerous in overdose than SSRIs. Among newer antidepressants, it ranks #2 for overdose mortality (behind bupropion). Overdose can produce seizures, cardiac conduction effects, and serotonin toxicity.

Keep the absolute risk in perspective, though. The fatal-toxicity index remains far below that of the tricyclics, which are lethal in overdose. The relative ranking is real, but the absolute risk in a given patient is low. In a high-risk, actively suicidal patient the overdose risk still deserves weight: favor a safer-in-overdose agent, or limit dispensed quantities.

Serotonin Syndrome

A labeled risk when combined with MAOIs or other serotonergic agents; see Interactions.

Part 8: Drug Interactions

Venlafaxine is relatively, but not perfectly, clean.

Metabolism

• Primary: CYP2D6. Secondary: CYP3A4.
• Converted to the active metabolite desvenlafaxine (marketed as Pristiq).
• Venlafaxine is only a weak 2D6 inhibitor, so it rarely raises other drugs' levels meaningfully.

Why 2D6 Interactions Mostly Wash Out

When a 2D6 inhibitor is added (paroxetine, fluoxetine and bupropion are strong; duloxetine is moderate), venlafaxine levels rise, but less parent drug converts to desvenlafaxine, so the active metabolite falls. Because parent and metabolite are roughly equipotent, the net pharmacologic effect is close to a wash. That is why venlafaxine tolerates 2D6 inhibitors better than you'd expect.

Interactions That DO Matter

• MAOIs: absolute contraindication. Current use or within 14 days. Serotonin syndrome. (Includes linezolid and methylene blue, which have MAOI activity.)
• Other serotonergic agents (SSRIs, other SNRIs, tramadol, dextromethorphan, St. John's wort, buspirone): serotonin syndrome risk, combine cautiously. (Note: the triptan-SNRI combination, despite an old FDA warning, is now considered safe; large studies found no increased serotonin-syndrome risk.)
• Sympathomimetics (stimulants, pseudoephedrine, other noradrenergic agents like atomoxetine): additive hypertension risk from stacked noradrenergic drive. Avoid unintended stacking.
• NSAIDs / antiplatelets / warfarin: additive bleeding risk (add a PPI in higher-risk patients).
• Methadone: be cautious with methadone polypharmacy (torsades risk in that context); avoid if possible.
• St. John's wort: serotonin syndrome risk and it induces CYP3A4, potentially lowering venlafaxine levels.

Cleaner Alternatives If Interactions Dominate

If minimizing interactions is the priority, citalopram, escitalopram, sertraline, and desvenlafaxine are cleaner. Desvenlafaxine (glucuronidated, bypassing CYP450) is the lowest-interaction SNRI, which is its main practical advantage over venlafaxine.

Part 9: Special Populations

Pregnancy

Reassuring, on balance. Commonly used antidepressants including SNRIs are not associated with an increased risk of congenital malformations or autism (Mezzacappa 2017). Venlafaxine is not flagged like paroxetine (which carries the worst reputation). The considerations:

• Third-trimester exposure can cause poor neonatal adaptation (jitteriness, irritability, abnormal tone, feeding issues), self-limited.
• PPHN (persistent pulmonary hypertension of the newborn) is a rare SSRI concern; less studied with SNRIs.
• General approach: minimize exposures, but treat maternal illness, and use the antidepressant the patient previously responded to rather than switching for theoretical safety. Untreated depression carries its own substantial risks.

Lactation

SNRIs are minimally excreted into breast milk and generally considered low-risk. Among all antidepressants, sertraline has the most favorable and best-studied lactation profile; venlafaxine is probably acceptable but less studied. If a patient is doing well on venlafaxine, continuing while breastfeeding is reasonable with pediatric coordination and infant monitoring.

Elderly

• Start low, go slow. Titrate more gradually.
• Blood pressure monitoring matters more here.
• Expect a weaker antidepressant response: a mega-analysis found the response in patients >55 was markedly smaller than in young adults (CGI-S coefficient −0.16 vs. −0.67 in ages 21 to 35), and males responded less than females across all ages. Anticipate this and consider adjunctive psychotherapy.
• Not a preferred first-line agent in the elderly: sertraline and citalopram (mind the QT ceiling) are gentler, once-daily, low-interaction choices, and venlafaxine adds hypertension risk and a hard discontinuation.
• Off-label option: venlafaxine plus aripiprazole (2 to 15 mg) augmentation in late-life TRD gave 44% remission vs. 29% placebo (Lenze, Lancet 2015), but more akathisia (26% vs. 12%) and parkinsonism (17% vs. 2%).

Renal and Hepatic Impairment

• Both require dose reduction, roughly 25 to 50%. Venlafaxine is minimally removed by hemodialysis; give the daily dose after the dialysis session and reduce the total daily dose by about 50%.
• FDA warns of serious cardiovascular/hepatic effects at higher doses in hepatic impairment.
• Titrate cautiously and cap the dose lower in these patients.

Poor CYP2D6 Metabolizers

Whether genetic or from a 2D6-inhibiting comedication, poor metabolizers accumulate more parent drug. Titrate slower, roughly half-steps, and watch tolerability. Pharmacogenetic 2D6 status, if available, can predict who tolerates escalation and who accumulates.

Pediatric

• No SNRI has strong pediatric depression data; among SNRIs, only duloxetine carries a pediatric FDA indication (GAD, age 7+). Venlafaxine in children is second-line after SSRIs at best, and poorly studied.
• The suicidality boxed warning applies.

Bipolar Depression

Antidepressant monotherapy is generally avoided in bipolar disorder, and venlafaxine has the least reassuring switch data of the usual options. In a 10-week randomized trial of 174 patients given an antidepressant alongside a mood stabilizer, switches into hypomania or mania were significantly more frequent on venlafaxine than on bupropion or sertraline. A 2025 network meta-analysis of 13 trials (1,362 patients) found no antidepressant significantly riskier than placebo, though venlafaxine carried the highest risk estimate and was the only drug with a consistent switch signal across individual studies. Treat it as a later choice in bipolar depression. Always pair with a mood stabilizer; never use as bipolar monotherapy without careful thought.

Part 10: Venlafaxine vs. the Alternatives

• vs. SSRIs: venlafaxine is marginally more effective (45% vs. 35% remission; ~1 extra remission per 10 to 24 treated) but has a much worse discontinuation syndrome and few clear tolerability advantages. SSRIs win for a first, uncomplicated trial; venlafaxine wins as a second move, for dual-mechanism needs, and for pain.
• vs. Desvenlafaxine (Pristiq): Pristiq is venlafaxine's own active metabolite, repackaged. It offers no efficacy advantage, no dose-response (a liability, not a convenience), and never won European approval, the manufacturer having withdrawn its EU application in 2008 while the CHMP's provisional view was that desvenlafaxine looked less effective than venlafaxine with no safety or tolerability advantage. Its only real edge is a cleaner interaction profile (glucuronidation, no CYP450). For most patients, prescribe the cheaper parent drug; reserve Pristiq for the polypharmacy patient in whom CYP interactions are a real problem. TCPR's verdict: "not a novel antidepressant."
• vs. Duloxetine (Cymbalta): similar efficacy; both SNRIs. Duloxetine has FDA pain indications (diabetic neuropathy, fibromyalgia), somewhat easier titration, and a milder (but still real) discontinuation profile, but carries a hepatotoxicity signal (avoid in heavy drinkers). Venlafaxine has better neuropathic-pain data (NNT ~3 vs. ~5). Duloxetine is often the friendlier SNRI; venlafaxine the more potent-at-high-dose one.
• vs. Bupropion: bupropion is preferred for uncomplicated depression without prominent anxiety: no nausea, no sexual dysfunction, minimal discontinuation, and it aids energy and (mildly) weight. STAR*D found no remission difference between switching to venlafaxine, bupropion, or sertraline. If sexual side effects or withdrawal burden are the concern, bupropion wins.
• vs. Mirtazapine augmentation ("California Rocket Fuel"): the once-popular venlafaxine plus mirtazapine combination looked elegant on paper (mirtazapine blunts SNRI nausea and sexual dysfunction while boosting release), but recent RCTs failed to separate it from placebo (remission ~24 to 29% vs. ~25%). Not recommended as a routine strategy on current evidence.
• In network meta-analysis (Cipriani 2018): venlafaxine ranks high for efficacy but has among the worst dropout/acceptability (near amitriptyline). That ranking sums up the drug: effective, but poorly tolerated to start and to stop.

Venlafaxine isn't first-line mainly because of the discontinuation syndrome, and also because SSRIs are gentler for an opening move and its efficacy edge is modest. None of that makes it a bad drug. It is a deliberate second choice, and it repays being used for a reason.

Mechanism

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor, but the "dual" label oversells its balance. Its potency ratio is roughly 120:1 in favor of serotonin. In practice:

• Below ~150 mg/day, it behaves essentially like an SSRI: predominantly serotonin reuptake blockade.
• At ~150 mg/day and above, meaningful norepinephrine reuptake inhibition kicks in, and it becomes a true dual agent, approaching the pharmacology of the tricyclic clomipramine at higher doses. (At very high doses a weak dopaminergic effect may emerge, but this is minor and not the basis of its action.)

This dose-dependent dual mechanism explains three clinical facts: the BP-raising effect (noradrenergic), the efficacy that keeps climbing with dose (recruiting NE), and its analgesic activity in neuropathic pain and migraine (descending noradrenergic pain modulation). It is metabolized by CYP2D6 to the equipotent desvenlafaxine, and its short half-life (~5 h parent; ~11 h metabolite) is the direct cause of its brutal discontinuation syndrome.

The Bedside Cheat Sheet